CD274 and neoplasm: Unlike other anti–PD-L1/PD-1 antibodies, avelumab contains a native Fc region and is capable of engaging natural killer cells to induce innate effector function against tumor cells, as shown in preclinical models [14, 15]; additional investigation is needed to determine the contribution of innate effector function to the overall antitumor response of avelumab.